Trial · NCT02555748
Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma
NCT02555748, Phase 4, Completed, Institut Claudius Regaud
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma. Trials, record NCT02555748. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02555748
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma
- NCT number
- NCT02555748
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 47 participants, actual
- Lead sponsor
- Institut Claudius Regaud
- Conditions
- Metastatic Renal Cell Cancer
- Interventions
- Pazopanib, Sunitinib
- First posted
- 2015-09-22
- Last updated
- 2026-03-31
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Part I: Pharmacokinetics - Pazopanib or Sunitinib plasma concentrations | On day 1 and day 15 during cycle 1 and cycle 2 (cycle length is 6 weeks) | |
| Primary | Part II: Tolerance - Proportion of patients without treatment discontinuation due to adverse event (AE) during the first year. | 5.5 years | This corresponds to the number of patients without treatment discontinuation due to AE among the total number of patients in each group. |
| Primary | Part II: Efficacy - Proportion of patients without progression at 1 year. This corresponds to the number of patients without progression at 1 year among the total number of patients in each group | 5.5 years | |
| Primary | Part I: Adverse Events according to NCI toxicity scale (version 4.03) | 1.5 years | |
| Secondary | Part I and II: Objective Response (e.g. Complete or Partial Response) | 5.5 years | Objective Response will be defined using RECIST Criteria version 1.1. |
| Secondary | Part I and II:- Progression free survival. | 5.5 years | Progression free survival is defined as the time from inclusion until progression (RECIST Criteria version 1.1) or death. Patients alive at last follow-up news are censored at this date. |
| Secondary | Part I and II: Safety according to the classification of the NCI: Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.03. | 5.5 years | |
| Secondary | Part I and II: Hand-foot syndrome (HFS) | 5.5 years | Hand-foot syndrome (HFS) will be evaluated using the HFS-14 questionnaire. This scale specifically developed for patients with HFS is a valid and valuable tool for measuring HFS-related QoL impairment. |
| Secondary | Part I and II: Quality of life using the quality of life questionnaire (QLQ)-C30 | 5.5 years | Quality of life will be evaluated using the QLQ-C30 questionnaire |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 41801644 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02555748
GET https://conductscience.org/api/trials/v1/NCT02555748/registered